The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
June 28, 2021
View Complete Issue         Table of Contents 2019 
Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only)
June 28, 2021 (Issue: 1627)
Casimersen (Amondys 45 – Sarepta), an IV antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have mutations of the dystrophin gene that are amenable to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only)
Article code: 1627e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.